Amphista Therapeutics to Showcase Three Cancer Drug Candidates at AACR 2026
Event summary
- Amphista Therapeutics will present three drug candidates at the AACR 2026 Annual Meeting in April.
- The presentations include an oral session on AMX-883, a BRD9 degrader for AML treatment.
- Two poster sessions will detail novel degraders for SMARCA2 and TEAD targets in cancer.
- The SMARCA2 degrader shows >95% degradation within 4 hours in preclinical studies.
The big picture
Amphista's presentations at AACR 2026 highlight its focus on next-generation targeted protein degraders, a growing area in oncology. The company's proprietary Eclipsys® platform aims to overcome limitations of current degradation technologies, positioning it in a competitive landscape with other biotechs developing similar approaches. Success in these programs could validate Amphista's platform and attract further investment.
What we're watching
- Clinical Validation
- Whether AMX-883 can demonstrate efficacy in AML patients regardless of genetic profile.
- Competitive Positioning
- How Amphista's non-cereblon/non-VHL degraders differentiate from existing approaches.
- Investor Interest
- The pace at which Amphista can secure additional funding for late-stage development.
Related topics